Urinary Volatile Compounds as Biomarkers for Lung Cancer

  • HANAI Yosuke
    Bioscience Technology Development Office, Panasonic Corporation Bioscience Technology Development Office, Panasonic Corporation
  • SHIMONO Ken
    Bioscience Technology Development Office, Panasonic Corporation Bioscience Technology Development Office, Panasonic Corporation
  • MATSUMURA Koichi
    Monell Chemical Senses Center Monell Chemical Senses Center
  • VACHANI Anil
    University of Pennsylvania Medical Center University of Pennsylvania Medical Center
  • ALBELDA Steven
    University of Pennsylvania Medical Center University of Pennsylvania Medical Center
  • YAMAZAKI Kunio
    Monell Chemical Senses Center Monell Chemical Senses Center
  • BEAUCHAMP Gary K.
    Monell Chemical Senses Center Monell Chemical Senses Center
  • OKA Hiroaki
    Bioscience Technology Development Office, Panasonic Corporation Bioscience Technology Development Office, Panasonic Corporation

この論文をさがす

抄録

Lung cancer is a leading cause of deaths in cancer. Hence, developing early-stage diagnostic tests that are non-invasive, highly sensitive, and specific is crucial. In this study, we investigated to determine whether biomarkers derived from urinary volatile organic compounds (VOCs) can be used to discriminate between lung cancer patients and normal control patients. The VOCs were extracted from the headspace by solid-phase microextraction and were analyzed by gas chromatography time-of-flight mass spectrometry. Nine putative volatile biomarkers were identified as elevated in the lung cancer group. Receiver operating characteristic curve analysis was also performed, and the markers were found to be highly sensitive and specific. Next we used principal component analysis (PCA) modeling to make comparisons compare within the lung cancer group, and found that 2-pentanone may have utility in differentiating between adenocarcinoma and squamous cell carcinomas.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (44)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ